Compare HubSpot Inc (HUBS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Sana Biotechnology Inc — how do they compare? HubSpot Inc trades at $229.3 (market cap $11.56B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: HubSpot Inc is far larger — about 13.8× Sana Biotechnology Inc's market cap, and HubSpot Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Sana Biotechnology Inc for 23 Days on average.
| HUBS | SANA | |
|---|---|---|
Market Cap | $11.56B | $836.71M |
Volume | 1,891,287 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $494.58 | $5.92 |
52-Week Low | $170.39 | $2.68 |
Typical Hold Time | 78 Days | 23 Days |
Enterprise Value | $10.46B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $228.96, up 3.93% with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth, reaching $3.13B in 2025 with net income turning positive at $45.91M. Recent analyst day highlighted AI strategy enhancements and margin expansion targets, while institutional buying and positive earnings beats support investor confidence. Technical indicators show the stock trading near pivot point resistance at $228 with RSI suggesting potential overbought conditions.
Outlook remains positive with 57% analyst buy ratings and $243.65 consensus target, though high P/E of 82.5x demands sustained growth execution. Key risks include AI competition pressure and valuation sensitivity to earnings momentum. The transition to profitability and strong cash flow generation provide fundamental support for continued upside potential.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
